|1.||Yamaguchi, Akio: 1 article (11/2013)|
|2.||Muramatsu, Ikunobu: 1 article (11/2013)|
|3.||Kobayashi, Tadashi: 1 article (11/2013)|
|4.||Takahashi, Toshihiro: 1 article (11/2013)|
|5.||Umada, Hidenori: 1 article (11/2013)|
|6.||Yokoyama, Osamu: 1 article (11/2013)|
|7.||Yoshiki, Hatsumi: 1 article (11/2013)|
|8.||Yamakawa, Tomio: 1 article (11/2013)|
|9.||Uwada, Junsuke: 1 article (11/2013)|
|10.||Shah, Monty: 1 article (01/2006)|
|1.||Stress Urinary Incontinence
09/01/1999 - "NS-49 may therefore be useful for the treatment of urinary stress incontinence, with minimal side-effects because it has subtype selectivity."
11/01/2013 - "A series of drugs (A61603, Ro 115-1240, NS-49 , MK017 and ESR1150) originally developed for stress urinary incontinence (SUI) therapy were used to stimulate recombinant α1A - and α1L -adrenoceptor phenotypes, and their potencies and intrinsic activity estimated from Ca(2+) responses. "
|2.||Renal Insufficiency (Renal Failure)
08/05/1999 - "Effects of renal insufficiency and of aging on the pharmacokinetics of NS-49, a newly developed phenethylamine class alpha(1A)-adrenoceptor agonist eliminated mainly by renal excretion, were investigated in rats after a single administration of (14)C-NS-49. "
08/05/1999 - "Effects of renal insufficiency and aging on the pharmacokinetics of a phenethylamine class alpha(1A)-adrenoceptor agonist NS-49."
01/01/2006 - "Demographics of CAM use: 47% of Caucasians, compared to 29% of African-Americans (OR=2.2, p=0.03); 44% of females, compared to 34% of males (p=NS); 49% of patients</=60 years old, compared to 32% of patients>60 years old (OR=2.0, p=0.04); 48% of patients with a cancer diagnosis, compared to 31% of patients with a benign diagnosis (OR=3.1, p=0.04). "